We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid Hepatitis C Virus POC Test Evaluated

By LabMedica International staff writers
Posted on 05 Apr 2018
Current hepatitis C (HCV) testing includes two clinical visits. More...
In the first visit, clinicians test for HCV antibodies, which would confirm only that the patient has been exposed to the virus. A second visit includes testing for HCV RNA to determine the presence of active infection.

Point-of-care hepatitis C virus (HCV) RNA testing is advantageous enabling diagnosis of active infection in a single visit. Previous studies have shown that patients are lost to follow up because they do not return for subsequent visits, and that the process can be difficult without a phlebotomist and for people who inject drugs (PWID), whose veins can be difficult to access.

Scientists at the University of New South Wales (Sydney, Australia) and their colleagues enrolled participants between August 3, 2016, and December 13, 2016, at three drug treatment clinics and a service for homeless people in Australia. A total of 223 participants enrolled, 72% had a history of injection drug use, and 46% had injected within the previous month of enrollment.

The investigators evaluated the sensitivity and specificity of the Xpert HCV Viral Load Fingerstick assay for HCV RNA detection (finger-stick) and the Xpert HCV Viral Load assay (plasma) compared with the Abbott RealTime HCV Viral Load assay by venipuncture.

The authors found that of 223 participants enrolled, HCV RNA was detected in 40% of participants (85 of 210) with available Xpert HCV Viral Load testing. Participants receiving HCV therapy were excluded from subsequent analyses. Sensitivity of the Xpert HCV Viral Load assay for HCV RNA quantification in plasma collected by venipuncture was 100% and specificity was 100%. Sensitivity of the Xpert HCV VL FS assay for HCV RNA quantification in samples collected by finger-stick was 100% and specificity was also 100%.

The authors concluded this test provides a major advance over antibody-based point-of-care tests, which only indicate HCV exposure. Further, the novel Xpert VL FS assay provides a substantial advance over the [current] Xpert HCV Viral Load assay, avoiding the need for plasma separation and enabling testing and diagnosis in one hour as compared to two hours, increasing the potential to move toward a single-visit diagnosis. The study was published on March 9, 2018, in The Journal of Infectious Diseases.

Related Links:
University of New South Wales


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.